2026-07-21T14:20:14Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/200252024-11-28T21:09:04Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Cassinello, J. author Climent, M. A. author Gonzalez Del Alba, Aranzazu author Mellado, B. author Virizuela, J. A. author 2014-12 Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently required. Cassinello J, Climent MA, Gonzalez Del Alba A, Mellado B, Virizuela JA. SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014 Dec;16(12):1060-6. Epub 2014 Oct 16. 10.1007/s12094-014-1225-3 1699-3055 1699-048X Clinical & Translational Oncology http://hdl.handle.net/20.500.13003/11050 25319721 L600179806 2-s2.0-84919419308 http://hdl.handle.net/20.500.12105/20025 345397300006 Androgen deprivation treatment Castration-resistant prostate cancer Docetaxel Cabacitaxel Abiraterone Enzalutamide Radium 223 SEOM Clinical guidelines for the treatment of metastatic prostate cancer